Samsung, the market leader in Android-based mobile phones, is branching out into the pharmaceutical market by investing over $2 billion (with a B) into drugs that are no longer patented.
Samsung, the market leader in Android-based mobile phones, is branching out into the pharmaceutical market by investing over $2 billion (with a B) into drugs that are no longer patented.
